Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies-Reference-Cited by-同舟云学术

Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies

Published:2016-12-15 Issue:5 Volume:180 Page:735-737
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Prebet Thomas¹²^ORCID,Delaunay Jacques³,Wattel Eric⁴,Braun Thorsten⁵⁶,Cony-Makhoul Pascale⁷,Dimicoli Sophie⁸,Wickenhauser Stephan⁹,Lejeune Julie⁶¹⁰,Chevret Sylvie⁶¹⁰,Chermat Fatiha⁶¹¹,Fenaux Pierre⁶¹¹,Vey Norbert¹,

Affiliation:

1. Haematology Department; Institut PAOLI-CALMETTES and Aix-Marseille Université; Marseille France

2. Section of Hematology; Department of Internal Medicine; Yale University; New Haven CT USA

3. Haematology Department; Centre Hospitalo universitaire; Nantes France

4. Haematology Department; Hôpital Lyon Sud; Pierre-Bénite France

5. Haematology Department; Hôpital Avicenne; Bobigny France

6. Assistance Publique Hopitaux de Paris (AP-HP); Paris France

7. Haematology Department; Centre Hospitalier Annecy; Pringy France

8. Haematology Department; Centre Hospitalo Unversitaire Tripode; Pessac France

9. Haematology Department; Centre Hospitalo universitaire; Nimes France

10. Biostatistic Department; Hôpital Saint Louis; Paris France

11. Haematology Department; Hôpital Saint Louis; Paris France